FAQ on Quantum BioPharma Ltd.'s Special Dividend and Litigation Proceeds

What is Quantum BioPharma Ltd. planning to issue to its shareholders?

Quantum BioPharma Ltd. plans to issue a special dividend in the form of Contingent Value Rights (CVRs) to holders of its Class B Subordinate Voting Shares on a 1:1 basis, linked to potential proceeds from ongoing litigation.

What are the CVRs and how do they work?

The CVRs entitle shareholders to a pro rata share of between 10% and 50% of any net proceeds recovered from the company’s pending litigation. The exact payout percentage will be determined by the board at a later date.

Why is Quantum BioPharma issuing CVRs?

CEO Zeeshan Saeed stated the CVRs aim to align shareholder interests with potential legal outcomes from the company’s $700 million+ litigation against several banks over alleged stock manipulation.

Are the CVRs tradable?

No, the CVRs will be non-tradable, non-voting, and only payable in cash if funds are ultimately recovered from the litigation.

When will the record date for the CVRs be announced?

The record date for the CVRs has yet to be announced by Quantum BioPharma Ltd.

What is the focus of Quantum BioPharma Ltd.’s business?

Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, alcohol misuse disorders, and has a lead compound, Lucid-MS, for multiple sclerosis.

How can investors stay updated on Quantum BioPharma Ltd.?

Investors can find the latest news and updates relating to QNTM in the company’s newsroom at https://ibn.fm/QNTM.

What is TinyGems?

TinyGems is a specialized communications platform focusing on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio @ IBN, which includes access to a vast network of wire solutions and editorial syndication.